Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure-1 year results from the Ce mark trial

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F17%3A00075920" target="_blank" >RIV/00023001:_____/17:00075920 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://cardiothoracicsurgery.biomedcentral.com/track/pdf/10.1186/s13019-017-0587-3?site=cardiothoracicsurgery.biomedcentral.com" target="_blank" >https://cardiothoracicsurgery.biomedcentral.com/track/pdf/10.1186/s13019-017-0587-3?site=cardiothoracicsurgery.biomedcentral.com</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1186/s13019-017-0587-3" target="_blank" >10.1186/s13019-017-0587-3</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure-1 year results from the Ce mark trial

  • Popis výsledku v původním jazyce

    Background: The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility. The HeartMate 3 received market approval in the European Union in 2015 following completion of a multicenter study. After reaching the 6-month study endpoint, patients continue to be followed for 2 years with the 1-year results presented herein. Methods: A prospective, non-randomized study included adults with advanced heart failure and ejection fraction (EF) &lt;= 25%, cardiac index (CI) &lt;= 2.2 L/min/m(2) while not on inotropes, or inotrope dependent, or on optimal medical management for 45/60 days. Results: Fifty patients-54% bridge to transplant (BTT) and 46% destination therapy (DT)-were enrolled and implanted with the HeartMate 3. At baseline, 92% of the patients were INTERMACS profiles 2-4, with cardiac index 1.8 +/- 0.5 L/min/m(2) and 58% were supported with inotropes. At 1 year, 74% of the patients remain on support, 18% expired, 6% transplanted, and 2% explanted. The adverse events include 12% gastrointestinal bleeding, 16% driveline infections, 18% strokes, and 2% outflow graft thrombosis. There was no hemolysis, pump thrombosis or pump malfunction through 1 year. The six-minute walk test distance increased from a mean of 273 m to 371 m (P &lt; 0.0001). EQ-5D quality-of-life score increased from a mean of 52.7 to 70.8 (P = 0.0006). Conclusions: The 1-year HeartMate 3 LVAS results show survival and adverse-event profile are similar to other approved devices, with no pump thrombosis or pump failure. Patient&apos;s functional status and quality of life significantly improved over time.

  • Název v anglickém jazyce

    Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure-1 year results from the Ce mark trial

  • Popis výsledku anglicky

    Background: The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility. The HeartMate 3 received market approval in the European Union in 2015 following completion of a multicenter study. After reaching the 6-month study endpoint, patients continue to be followed for 2 years with the 1-year results presented herein. Methods: A prospective, non-randomized study included adults with advanced heart failure and ejection fraction (EF) &lt;= 25%, cardiac index (CI) &lt;= 2.2 L/min/m(2) while not on inotropes, or inotrope dependent, or on optimal medical management for 45/60 days. Results: Fifty patients-54% bridge to transplant (BTT) and 46% destination therapy (DT)-were enrolled and implanted with the HeartMate 3. At baseline, 92% of the patients were INTERMACS profiles 2-4, with cardiac index 1.8 +/- 0.5 L/min/m(2) and 58% were supported with inotropes. At 1 year, 74% of the patients remain on support, 18% expired, 6% transplanted, and 2% explanted. The adverse events include 12% gastrointestinal bleeding, 16% driveline infections, 18% strokes, and 2% outflow graft thrombosis. There was no hemolysis, pump thrombosis or pump malfunction through 1 year. The six-minute walk test distance increased from a mean of 273 m to 371 m (P &lt; 0.0001). EQ-5D quality-of-life score increased from a mean of 52.7 to 70.8 (P = 0.0006). Conclusions: The 1-year HeartMate 3 LVAS results show survival and adverse-event profile are similar to other approved devices, with no pump thrombosis or pump failure. Patient&apos;s functional status and quality of life significantly improved over time.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30201 - Cardiac and Cardiovascular systems

Návaznosti výsledku

  • Projekt

  • Návaznosti

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Ostatní

  • Rok uplatnění

    2017

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Journal of cardiothoracic surgery

  • ISSN

    1749-8090

  • e-ISSN

  • Svazek periodika

    12

  • Číslo periodika v rámci svazku

    April 4

  • Stát vydavatele periodika

    GB - Spojené království Velké Británie a Severního Irska

  • Počet stran výsledku

    8

  • Strana od-do

    "art. no. 23"

  • Kód UT WoS článku

    000398517800002

  • EID výsledku v databázi Scopus